Monday, January 26, 2015   

Japan’s Takeda to appeal US$6b diabetes drug verdict
(04-08 15:53)

A US jury ordered Japan’s Takeda Pharmaceuticals to pay US$6 billion in punitive damages over a diabetes drug, but the country’s biggest drug-maker is challenging the move.
The District Court, Western District Louisiana, on Tuesday also ordered a US$3 billion penalty for co-defendant Eli Lilly, as well as US$1.5 million in compensatory damages.
The legal fight was over Actos, a drug used to treat diabetes, as causing a patient's bladder cancer.
Takeda Senior Vice President Kenneth Greisman said in a statement that Takeda disagrees with the verdict and plans post-trial motions and an appeal.
He said he empathized with the plaintiff but the drug did not cause his cancer.
The drug comes with warnings about serious side effects, including liver problems, broken bones and higher risk of bladder cancer. –AP

   
Other Business breaking news:
Nikkei down by midday (38 mins ago)
Japan trade deficit swells to record in 2014 (39 mins ago)
ECB stimulus will boost China's exports: official (01-23 19:25)
More mainlanders visit HK last year: HKTB (01-23 19:24)
Eurozone economy picks up in January: survey (01-23 19:14)
Adidas says profits hit by falling ruble, divestment (01-23 18:55)
Ratio of Chinese banks' bad loans jumps in Q4 (01-23 18:42)
Use of yuan for cross-border business growing (01-23 18:28)
Hang Seng, Shanghai end higher (01-23 18:26)
European stocks open higher on ECB stimulus (01-23 18:25)

More breaking news >>

© 2015 The Standard, The Standard Newspapers Publishing Ltd.
Contact Us | About Us | Newsfeeds | Subscriptions | Print Ad. | Online Ad. | Street Pts

 


Home | Top News | Local | Business | China | ViewPoint | CityTalk | World | Sports | People | Central Station | Spree | Features

The Standard

Trademark and Copyright Notice: Copyright 2015, The Standard Newspaper Publishing Ltd., and its related entities. All rights reserved.  Use in whole or part of this site's content is prohibited.   Use of this Web site assumes acceptance of the
Terms of Use, Privacy Policy Statement and Copyright Policy.  Please also read our Ethics Statement.